Literature DB >> 12802926

Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide.

Tadeusz Robak1, Anna Szmigielska-Kapłon, Piotr Smolewski, Ewa Wawrzyniak, Anna Korycka, Jacek Bartkowiak, Radzisław Kordek.   

Abstract

Second malignancies are frequent complications in patients with chronic lymphocytic leukemia (CLL). Hodgkin's disease (HD) has been observed in approximately 0.5% of the patients with CLL and is known as Hodgkin's type Richter's syndrome (H-RS). We present a 64-year-old male patient with a familial history of CLL who developed H-RS in abdominal lymph nodes 6 years after CLL diagnosis and 18 months after treatment with cladribine (2-CdA) and cyclophosphamide. HD was diagnosed by fine needle aspiration. The disease was refractory to treatment with two courses of CHOP and three courses of ABVD chemotherapy. In the current literature we found case reports of only 6 patients with H-RS who were treated with fludarabine (FA) before transformation, and, to our knowledge the presented patient is the first to develop H-RS after treatment with 2-CdA combined with cyclophosphamide. He is also the first published patient with familial CLL in whom this complication developed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802926     DOI: 10.1080/1042819031000063417

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

Review 1.  Familial chronic lymphocytic leukemia: what does it mean to me?

Authors:  Susan L Slager; Neil E Kay
Journal:  Clin Lymphoma Myeloma       Date:  2009

2.  A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

Authors:  Judith E Karp; Rebecca M Ricklis; Kumudha Balakrishnan; Janet Briel; Jacqueline Greer; Steven D Gore; B Douglas Smith; Michael A McDevitt; Hetty Carraway; Mark J Levis; Varsha Gandhi
Journal:  Blood       Date:  2007-06-11       Impact factor: 22.113

Review 3.  Second neoplasms in patients with chronic lymphocytic leukemia.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2004-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.